Patents Examined by Elizabeth C. Kemmerer
  • Patent number: 10400036
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: September 3, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 10385127
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: August 20, 2019
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
  • Patent number: 10377819
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 13, 2019
    Assignees: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Patent number: 10377801
    Abstract: Provided herein are compositions and methods for the treatment of Chronic Kidney Disease (CKD) and/or the amelioration or prevention of symptoms, conditions and diseases associated therewith.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: August 13, 2019
    Assignee: Northwestern University
    Inventors: Aline C. Martin, Nicolae V. David, Myles S. Wolf
  • Patent number: 10357542
    Abstract: The present invention provides composition and methods for diagnosis and treatment of lysosomal storage diseases and their diagnosis and treatment, including Gaucher's Disease and Tay-Sachs disease, and particularly which utilize progranulin (PGRN), or active PGRN peptides, including atsttrin. The invention also provides animal models of lysosomal storage diseases, including Gaucher's Disease and Tay-Sachs disease, based on or including PGRN mutations including PGRN null mutants and PGRN gene knock outs.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: July 23, 2019
    Assignee: New York University
    Inventors: Chuanju Liu, Jinlong Jian
  • Patent number: 10357511
    Abstract: Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosis-inducing activity, differentiation-inducing activity, chemotactic activity, angiogenic or vasculogenic activity, and exocytosis or endocytosis-inducing activity. In one embodiment, a method for producing an osteoinductive composition comprises providing partially demineralized bone, treating the partially demineralized bone to disrupt the collagen structure of the bone. In another embodiment, an implantable osteoinductive and osteoconductive composition comprises partially demineralized bone, wherein the collagen structure of the bone has been disrupted, and, optionally, a tissue-derived extract.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 23, 2019
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Keyvan Behnam, Guobao Wei, Nanette Forsyth
  • Patent number: 10336798
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: July 2, 2019
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle M. Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Kenneth W. Walker, Bryan Lemon
  • Patent number: 10336812
    Abstract: Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: July 2, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Anthony Armstrong, Judith Ann Connor, Jennifer Furman, Chichi Huang, Michael J. Hunter, Xiefan Lin-Schmidt, Serena Nelson, Shamina Rangwala, Shannon Mullican, Jose Antonio Chavez
  • Patent number: 10336800
    Abstract: The invention relates to a polypeptide selected from bone morphogenetic protein 10 (BMP10), or a bone morphogenetic protein 9 (BMP9) variant lacking osteogenic activity, for use in the treatment of a vascular disease or a respiratory disease. The invention also relates to novel BMP9 variants and to pharmaceutical compositions comprising said polypeptides.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: July 2, 2019
    Assignee: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Nicholas W. Morrell, Wei Li, Paul D Upton
  • Patent number: 10323074
    Abstract: The disclosure features, among other things, polypeptides comprising a Cryptic polypeptide, a functional fragment thereof, or variants of any of the foregoing. Also featured are nucleic acids encoding the polypeptides, methods for producing of the polypeptides, and a variety of diagnostic and therapeutic applications in which the polypeptides are useful. For example, the polypeptides can be used to treat a subject having a condition associated with bone loss.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: June 18, 2019
    Assignee: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: Erik Martinez-Hackert, Senem Aykul
  • Patent number: 10323075
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: June 18, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar, Geoffrey Horner
  • Patent number: 10316096
    Abstract: The present invention relates to antibody-containing lyophilized formulations free from reducing sugars, non-reducing sugars, sugar alcohols or polysaccharides as excipients and including one or more amino acid selected from the group consisting of arginine, histidine, lysine, serine, proline, glycine, alanine and threonine or a salt thereof.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: June 11, 2019
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Toshiyuki Morichika, Daisuke Kameoka
  • Patent number: 10308695
    Abstract: Disclosed are isolated mutant erythropoietin (EPO) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant EPO peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substation at position 76. This substitution inhibits erythropoietic activity while retaining their neuroprotection. Also disclosed are methods of treating or inhibiting neuronal degeneration, reducing or inhibiting one or more symptoms associated with neuronal degeneration and/or glaucoma in a subject. The methods include administering a therapeutically effective amount of a isolated mutant erythropoietin EPO polypeptide, an expression vector encoding such a mutant erythropoietin EPO polypeptide, a viral particle including an expression vector, or a composition, thereby treating or inhibiting neuronal degeneration in the subject.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 4, 2019
    Assignee: Vanderbilt University
    Inventors: Tonia S. Rex, Timothy A. Sullivan
  • Patent number: 10308715
    Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: June 4, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshiharu Hiruma, Eisuke Tsuda
  • Patent number: 10287336
    Abstract: The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: May 14, 2019
    Assignee: AskGene Pharma, Inc.
    Inventors: Jian-Feng Lu, Yuefeng Lu, Aijun Wang, Donggou He, Kurt Shanebeck, Chen Yao
  • Patent number: 10280218
    Abstract: The present invention relates to antibody which binds to an epitope located within the BMPR1 binding region of BMP4.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: May 7, 2019
    Assignee: ACADEMISCH MEDISCH CENTRUM
    Inventors: Kausilia Krishnawatie Krishnadath, Silvia Calpe
  • Patent number: 10279011
    Abstract: The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: May 7, 2019
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jarrod Dudakov, Marcel van den Brink, Alan Hanash
  • Patent number: 10279047
    Abstract: Described herein are compounds, compositions and methods for modification of the surface of a living cell with a therapeutically relevant targeting moiety. Also described herein are methods for treating disease states, such as acute myocardial ischemia or infarction, with said compositions, in a subject.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: May 7, 2019
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Young-Wook Won, David A. Bull, Amit N. Patel
  • Patent number: 10265437
    Abstract: This disclosure relates to methods for promoting bone formation or reducing bone destruction. This disclosure also relates to methods for promoting the recruitment of mesenchymal stem cells (MSCs) to a local site of injury or surgical intervention in bone to promote healing. In addition, this disclosure relates to methods for reducing or preventing mineral formation or bone growth, or reducing bone mass. The methods disclosed herein are useful for treating conditions such as osteopetrosis or osteoradionecrosis.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: April 23, 2019
    Assignee: The Research Foundation for the State University of New York
    Inventors: Bryan S. Margulies, Sean D. Deboyace
  • Patent number: 10259861
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: April 16, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar